Stifel Nicolaus Boosts Denali Therapeutics (NASDAQ:DNLI) Price Target to $41.00

Denali Therapeutics (NASDAQ:DNLI) had its price target hoisted by equities research analysts at Stifel Nicolaus from $34.00 to $41.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 125.77% from the company’s previous close.

DNLI has been the subject of several other research reports. UBS Group started coverage on Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating for the company. BTIG Research lifted their price target on Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird upped their price target on Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Thursday. Wedbush reduced their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Finally, Wolfe Research began coverage on Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $34.82.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $18.16 on Thursday. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77. The firm’s fifty day simple moving average is $20.43 and its 200 day simple moving average is $17.83. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2.88 billion, a PE ratio of -6.11 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the prior year, the firm earned ($0.67) EPS. On average, sell-side analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Activity

In related news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is currently owned by company insiders.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently modified their holdings of DNLI. Headlands Technologies LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new position in Denali Therapeutics in the third quarter worth $29,000. State of Wyoming bought a new position in Denali Therapeutics in the second quarter worth $29,000. Aster Capital Management DIFC Ltd acquired a new stake in Denali Therapeutics during the fourth quarter worth $57,000. Finally, Quarry LP acquired a new stake in Denali Therapeutics during the third quarter worth $64,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.